TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Presence of neurogenic detrusor overactivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Regional cerebral perfusion (ml/100g/min)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Patient engagement in formal addiction treatment
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Maximum Observed Plasma Concentration (Cmax) of LOXO-305
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Concentration Versus Time Curve From Time Zero to the Last Measurable Concentration (AUC0-t) of LOXO-305
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Concentration Versus Time Curve From Time Zero to Infinity (AUC0-inf) of LOXO-305
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Relief degree
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Serum procalcitonin levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Mouth air leak
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Glasgow Coma Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in motor power on motor system examination
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Presence or absence of aphasia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Maximum tolerated dose of imatinib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to onset of first 1 day heartburn free
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: electric activity of leg muscles
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Diagnostic accuracy of transcriptional biomarkers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Major Adverse Cardiovascular and Cerebrovascular Events (MACCE) Rate
Endpoint domain: Mortality/survival
Primary endpoint: Percentage of Participants With Overall Device Success
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Cardiac-related Death
Endpoint domain: Mortality/survival
Primary endpoint: Change in Seated Diastolic Blood Pressure (SDBP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Counts of viable fecal bacterial cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Kuder Richardson Coefficient of reliability (K-R 20)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: all-cause hospital admission
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Time to HIV-1 related clinical events
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Total Clamp Disposition Index (cDI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bacteriological outcome
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Cognitive Status
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Progression free survival rates
Endpoint domain: Mortality/survival
Primary endpoint: Incidence of TMAs
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With X-ray of Either Hand With Bone Obscuration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Percentage of change for Quality of Life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: mean of patients' median blood glucose during ICU stay
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: incidence of hypoglycemia (≤40 mg/dL) during ICU stay
Endpoint domain: Adverse events/effects
Primary endpoint: Elimination of MRSA infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Mean Left Ventricular Ejection Fraction (LVEF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Time to achieve continence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of Procedure-related Mortality
Endpoint domain: Mortality/survival
Primary endpoint: Dichotomized Modified Rankin Scale (mRS) at Day 180
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Acceptability to patients with acute psychotic illnesses
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Earlier onset of parkinsonism assessed by micrographic changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Rabies specific regulatory T cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Rabies specific regulatory B cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Rabies specific T follicular helper cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Repigmentation of vitiligo patch
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: 180 day rehospitalization rate
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: ER visits
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: LOS
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Number of Participants With Response at Week 4
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Steroid-Free Remission at Week 50
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in relative attachment level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Biphasic Alcohol Effects Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the curve (AUC) of postprandial triglyceridemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Virologic Status
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 5,6-EET quantity in colonic biopsy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: number of anesthetized patients with perioperative critical incidence
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants Successfully Contributing MRI Data
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Sexual function
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Area under the serum Insulin Degludec concentration-time curve
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: User Sensory Perception
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of Participants Without Major Device-related Adverse Events and/or Failures
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants With No Histologic Evidence of Vulvar HSIL and No Evidence of HPV-16 and/or HPV-18
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Cesarean Delivery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: COWS Total Score AUC
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Maximum Cystometric Capacity (MCC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Percent Changes From Baseline in Pruritus Visual Analogue Scale (VAS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Number of Days With Self-report of No Smoking
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Breath Carbon Monoxide of <5 PPM
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Curve (AUC 0-∞) ng∙h/mL
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maintenance of Entrainment (aMT6s)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Primary Composite End Point
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Geometric Mean Concentration (GMC) for Serotype-specific Pneumococcal IgG Antibody
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Difference in CD4+ T Cell Percentage Between Week 0 and Week 48
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Difference in CD4+ T Cell Percentage Between Week 48 and Week 152
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Area Under the Curve Extrapolated to Infinity for the Plasma Concentration Versus Time Curves for Telavancin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Plasma Concentration of Telavancin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Terminal Elimination Half-life for Plasma Telavancin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Glucose Tolerance at 24 Weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Glucose Tolerance at 48 Weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Insulin Sensitivity Index for Glycemia at 24 Weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Insulin Sensitivity Index for Glycemia at 48 Weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change From Baseline in 18F-FLT-PET Mean Standardized Uptake Value (SUVmean)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in 18F-FLT-PET Maximum Standardized Uptake Value (SUVmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Ki-67 Labeling Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to progression on combined HerChemo
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of deaths of any cause
Endpoint domain: Mortality/survival
Primary endpoint: Health Care Utilization Related to Study Results
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: size of scar
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Microbial Taxonomical Composition
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in overall level of PTSD
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in levels of PTSD symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Delivery before 37 weeks gestation
Endpoint domain: Mortality/survival
Primary endpoint: Lateral Condyle Kinematic Translations - Step up
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lateral Condyle Kinematics Translations - Deep Knee Bend
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Medial Condyle Kinematics Translations - Step Up
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Medial Condyle Kinematics Translations - Deep Knee Bend
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: treatment failure defined as viral load greater than 200 copies/ml
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: toxicity related to PI defined as adverse event grade 3 or 4
Endpoint domain: Adverse events/effects
Primary endpoint: Efficacy of prucalopride
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Occurrence of acute chest syndrome
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Incidence of Any Adjudicated Bleeding Events
Endpoint domain: Adverse events/effects
Primary endpoint: Change in the Maintenance of Wakefulness Test (MWT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in the Epworth Sleepiness Scale (ESS)
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Changes in Clinic Blood Pressure in the Sitting Position
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in Number of Total Collisions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Number of Centerline Crossings
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Number of Off-road Excursions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Subjects With Grade 3, 4, or 5 Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Subjects With Immune-related Responses (irPR, irCR, irSD, irPD, irNE)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Subjects With Treatment Emergent Adverse Events Related to CC-486
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Subjects With Treatment Emergent Adverse Events Related to Pembrolizumab
Endpoint domain: Adverse events/effects
Primary endpoint: Mean concentration of Lipoprotein-associated Phospholipase A2 (LP-PL-A2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Mean concentration of Pregnancy-associated Plasma Protein A (PAPP A)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Mean concentration of Asymmetric Dimethylarginine (ADMA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Mean concentration of highsensitivity C-reactive Protein (hsCRP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean concentration of Lipprotein (a)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Recommended Phase 2 Dose (RP2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serious and Non-serious Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Absolute Change in IL-1beta Cytokine Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Concordance between S-MRCP and S-EUS
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Effectiveness of FA-ICG guided focal laser therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: accuracy of seizure detection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Levels of bioactive components in blood and urine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: p24 antigen production
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Analysis of integrated DNA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Anti-HIV activity in cervicovaginal fluid
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in BMI (BMI SDS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Monocyte NfkB Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Conjunctival Staining With Lissamine Green
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Women Achieving Vaginal Delivery Within 36 Hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Treatment Success With Respect to Blood Flow Rate (BFR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of Targeted Adverse Events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Change of estimated glomerular filtration rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Mean pain score during HSG
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Success of Prophylaxis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bladder volume measurement accuracy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Change from baseline in standardized uptake value ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Major acute cardiovascular events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Cases of condyloma post vaccination
Endpoint domain: Adverse events/effects
Primary endpoint: Variation of facial volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of ventilator-associated pneumonia (VAP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: All cause mortality of ICU and hospitalization
Endpoint domain: Mortality/survival
Primary endpoint: Improvement in patient quality of life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Confirmed objective response rate (confirmed ORR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in the Cerebral Palsy Quality of Life Questionnaire for Children
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Composite of death, myocardial infarction and target lesion revascularization
Endpoint domain: Mortality/survival
Primary endpoint: R0 Resection rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Survival rate at 2 years after transplantation
Endpoint domain: Mortality/survival
Primary endpoint: Measurement of skin texture
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Efficacy of pyrimethamine/sulfdoxine for malaria treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Balance Berg Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety and tolerability of TR-701 600mg
Endpoint domain: Adverse events/effects
Primary endpoint: Mini-Balance Evaluation System Score variation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of nodes detected
Endpoint domain: Physiological/clinical
Endpoint subdomain: Lymphatic system outcomes
Primary endpoint: Root mean square of successive inter beat interval differences (RMSSD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Standard deviation of normal to normal inter beat interval (SDNN)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Low frequency power/High frequency power (LF/HF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Incidence of Hand-Foot Syndrome
Endpoint domain: Adverse events/effects
Primary endpoint: SBA-MenC titre
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Anti-PRP concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Pain rating scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of risk factors for DVT
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Percentage of Patients Achieving HbA1c <=7%
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: No Gain in Body Weight From Baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: No Incidence of Severe Hypoglycemia
Endpoint domain: Adverse events/effects
Primary endpoint: Changes in cycloplegic refractive error
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Shoulder position measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence rate of postoperative pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: The degree of patients' satisfaction
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Chest pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Class IA Revascularizations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Percentage of Participants Achieving Clinical Response (HiSCR50)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total Body fat
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Visceral adipose tissue - VAT
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Average pain for the previous 24 hour period
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum pain intensity for the previous 24 hour period
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain at moment of examination
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean 24-hour Intraocular Pressure (IOP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes